Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Therapeutic Nuclear Drug Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The therapeutic nuclear drug market size has experienced swift growth in recent years. This market is projected to expand from $2.19 billion in 2025 to $2.51 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 14.5%. Historically, this expansion has been driven by factors such as the rising incidence of cancer, the early integration of iodine-131 for thyroid conditions, the restricted availability of targeted oncology treatments, the expansion of nuclear medicine departments, and a growing clinical acceptance of radiopharmaceuticals.
The therapeutic nuclear drug market is set for considerable expansion in the coming years, with its size anticipated to reach $4.27 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 14.3%. This projected growth stems from several factors, including the development of novel therapeutic isotopes, the widening scope of precision oncology approaches, greater investment in nuclear medicine infrastructure, an increase in clinical trials for radioligand therapies, and favorable regulatory approvals for targeted nuclear drugs. Furthermore, significant trends expected during this period involve the rising adoption of targeted radiopharmaceutical therapies, an increasing use of lutetium-177 and alpha-emitting isotopes, growth in cancer-specific nuclear drug applications, the expansion of combination therapies utilizing nuclear drugs, and a strengthening focus on safety dosimetry and regulatory compliance.
Get A Free Sample Report With In-Depth Market Insights:
Therapeutic Nuclear Drug Market Growth Catalysts And Demand Drivers
The rising incidence of cancer is anticipated to fuel the expansion of the therapeutic nuclear drug market in the future. Cancer is characterized by the uncontrolled growth and spread of abnormal cells. Its prevalence stems from factors such as improved detection and diagnosis, lifestyle choices, environmental exposures, and genetic predispositions. Therapeutic nuclear drugs are vital in the fight against cancer, offering targeted and effective treatment options that reduce tumor size, alleviate symptoms, and enhance patients’ quality of life. For instance, in February 2024, the World Health Organization, a Switzerland-based agency of the United Nations, projected that over 35 million new cancer cases will emerge by 2050, indicating a 77% increase from the estimated 20 million cases in 2022. Thus, the escalating prevalence of cancer is propelling the growth of the therapeutic nuclear drug market.
Therapeutic Nuclear Drug Market Segment Analysis And Revenue Potential
The therapeutic nuclear drug market covered in this report is segmented –
1) By Type: Radium-223, Lutetium-177, Iodine-131, Other Types
2) By Distribution Channel: Hospitals, Ambulatory Surgical Centers (ASCs), Cancer Research Institutes
3) By Application: Thyroid, Bone Metastasis, Lymphoma, Other Applications
Therapeutic Nuclear Drug Market Trends Shaping Long-Term Demand
Leading companies in the therapeutic nuclear drug market are advancing targeted radiotherapies, highlighting their novel potential for treating multiple tumors through emerging clinical data. These efforts are intended to strengthen innovation pathways, broaden therapeutic uses, and accelerate the adoption of next-generation radiopharmaceuticals. For example, in 2025, Actinium Pharmaceuticals, a US-based clinical-stage biopharmaceutical company, released new data for ATNM-400, its first-in-class Actinium-225 radiotherapy, demonstrating multi-tumor potential, including in non-small cell lung cancer (NSCLC). These findings were presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. ATNM-400 is engineered to deliver highly potent alpha-particle therapy with precise targeting, supporting its promise as a transformative therapeutic platform across various solid tumors. This advancement underscores the industry’s focus on expanding the clinical applications of actinium-based radiotherapies to improve patient outcomes and widen market opportunities.
Therapeutic Nuclear Drug Market Key Players Shaping Industry Direction
Major companies operating in the therapeutic nuclear drug market are Bayer AG, Novartis International AG, Siemens Healthineers AG, Ipsen S.A., Jubilant DraxImage Inc., Mallinckrodt Pharmaceuticals PLC, The Bracco Group, Lantheus Medical Imaging Inc., Piramal Group, Curium Pharmaceuticals, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Eckert & Ziegler, Telix Pharmaceuticals Limited, International Isotopes inc., Orano SA, Q BioMed Inc., Molecular Targeting Technologies Inc, Medi-Radiopharma Co. Ltd., Actinium Pharmaceuticals, Fusion Pharmaceuticals
View The Full Therapeutic Nuclear Drug Market Report:
Therapeutic Nuclear Drug Market Regional Analysis: Which Geography Leads On Revenue?
North America was the largest region in the therapeutic nuclear drug market in 2025. The regions covered in the therapeutic nuclear drug market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
